AstraZeneca: Imfinzi Plus Chemotherapy Doubled Overall Survival Rate at Three Years for Patients With Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial
April 17, 2024
April 17, 2024
WILMINGTON, Delaware, April 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
These results from TOPAZ-1, which are the longest survival f . . .
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
These results from TOPAZ-1, which are the longest survival f . . .